Monitoring physical and psychosocial symptom trajectories in ovarian cancer patients receiving chemotherapy

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Meraner, Verena ^a   Gamper, Eva Maria ^a   Grahmann, Anna ^b   Giesinger, Johannes M ^a   Wiesbauer, Petra ^a   Sztankay, Monika ^a   Zeimet, Alain G ^a   Sperner Unterweger, Barbara ^a   Holzner, Bernhard ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b NONE   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; ETOPOSIDE; PACLITAXEL;

ABDOMINAL DISEASE; ADULT; AFTERCARE; AGED; ANXIETY DISORDER; ARTICLE; ATTITUDE TO ILLNESS; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; EMOTIONALITY; FATIGUE; FEMALE; FUNCTIONAL STATUS; HUMAN; ILLNESS TRAJECTORY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVARY CANCER; PATIENT MONITORING; PHYSICAL DISEASE; PSYCHOSOCIAL DISORDER; QUALITY OF LIFE; SELF REPORT; SEXUAL FUNCTION; SYMPTOM;

EID: 84857412313     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-77     Document Type: Article

References (54)

1. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. 2010, Lyon, France: International Agency for Research on Cancer., http://globocan.iarc.fr
2. Wise J. Screening is effectiv in early detection of ovarian cancer. BMJ 2009, 338:b1084. 10.1136/bmj.b1084, 19293225.
3. Grab D, Flock F, Stohr I, Nussle K, Rieber A, Fenchel S, Brambs HJ, Reske SN, Kreienberg R. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol 2000, 77(3):454-459. 10.1006/gyno.2000.5768, 10831359.
4. Bethesda M. SEER Cancer Statistics Review, 195-2008 2011, Howlader N, Noone A, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse S, Kosary C, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisne rM, Lewis D, Chen H, Feuer E, Cronin K, Edwards B, National Cancer Institute. Bethesda M. Based on November 2010 SEER data submission, posted to the SEER web site., http://seer.cancer.gov/csr/1975_2008/
5. Helm CW, Bristow RE, Kusamura S, Baratti D, Deraco M. Hyperthermic Intraperitoneal Chemotherapy With and Without Cytoreductive Surgery for Epithelial Ovarian Cancer. J Surg Oncol 2008, 98:283-290. 10.1002/jso.21083, 18726895.
6. Aebi S, Pestalozzi BC, Thürlimann B. Chemotherapie des Ovarialkarzinoms. Curriculum Schweiz Med Forum 2003, 40:944-949.
7. Marsden DE, Friedlander M, Hacker NF. Current management of epithelial ovarian carcinoma: a review. Semin Surg Oncol 2000, 19(1):11-19. 10.1002/1098-2388(200007/08)19:1<11::AID-SSU3>3.0.CO;2-3, 10883019.
8. Donovan HS, Hartenbach EM, Method MW. Patient-provider communication and perceived control for women experiencing multiple symptoms associated with ovarian cancer. Gynecol Oncol 2005, 99(2):404-411. 10.1016/j.ygyno.2005.06.062, 16112174.
9. Ferrell B, Smith S, Cullinane C, Melancon C. Symptom concerns of women with ovarian cancer. J Pain Symptom Manage 2003, 25(6):528-538. 10.1016/S0885-3924(03)00148-9, 12782433.
10. Anderson NJ, Hacker ED. Fatigue in women receiving intraperitoneal chemotherapy for ovarian cancer: a review of contributing factors. Clin J Oncol Nurs 2008, 12(3):445-454. 10.1188/08.CJON.445-454, 18515243.
11. Houck K, Avis NE, Gallant JM, Fuller AF, Goodman A. Quality of life in advanced ovarian cancer: identifying specific concerns. J Palliat Med 1999, 2(4):397-402. 10.1089/jpm.1999.2.397, 15859780.
12. Holzner B, Kemmler G, Meraner V, Maislinger A, Kopp M, Bodner T, Nguyen Van Tam D, Zeimet AG, Fleischhacker WW, Sperner Unterweger B. Fatigue in ovarian carcinoma patients: a neglected issue?. Cancer 2003, 97(6):1564-1572. 10.1002/cncr.11253, 12627522.
13. Payne JK. The trajectory of fatigue in adult patients with breast and ovarian cancer receiving chemotherapy. Oncol Nurs Forum 2002, 29(9):1334-1340. 10.1188/02.ONF.1334-1340, 12370703.
14. Jensen SE, Rosenbloom SK, Beaumont JL, Abernethy A, Jacobsen PB, Syrjala K, Cella D. A new index of priority symptoms in advanced ovarian cancer. Gynecol Oncol 2011, 120(2):214-219. 10.1016/j.ygyno.2010.09.025, 21075440.
15. Cella D, Paul D, Yount S, Winn R, Chang CH, Banik D, Weeks J. What are the most important symptom targets when treating advanced cancer? A survey of providers in the National Comprehensive Cancer Network (NCCN). Cancer Invest 2003, 21(4):526-535. 10.1081/CNV-120022366, 14533442.
16. Stead ML, Brown JM, Fallowfield L, Selby P. Lack of communication between healthcare professionals and women with ovarian cancer about sexual issues. Br J Cancer 2003, 88(5):666-671. 10.1038/sj.bjc.6600799, 2376341, 12618871.
17. Fallowfield L, Ratcliffe D, Jenkins V, Saul J. Psychiatric morbidity and its recognition by doctors in patients with cancer. Br J Cancer 2001, 84(8):1011-1015. 10.1054/bjoc.2001.1724, 2363864, 11308246.
18. Lakusta CM, Atkinson MJ, Robinson J, Nation J, Taenzer PA, Campo MG. Quality of Life in Ovarian Cancer Patients Receiving Chemotherapy. Gynecol Oncol 2001, 81:490-495. 10.1006/gyno.2001.6199, 11371144.
19. Kornblith AB, Thaler HT, Wong G, Vlamis V, Lepore JM, Loseth DB, Hakes T, Hoskins WJ, Portenoy RK. Quality of life of women with ovarian cancer. Gynecol Oncol 1995, 59(2):231-242. 10.1006/gyno.1995.0014, 7590479.
20. Fox SW, Lyon D. Symptom clusters and quality of life in survivors of ovarian cancer. Cancer Nurs 2007, 30(5):354-361. 10.1097/01.NCC.0000290809.61206.ef, 17876181.
21. Le T, Hopkins L, Fung Kee Fung M. Quality of life assessments in epithelial ovarian cancer patients during and after chemotherapy. Int J Gynecol Cancer 2005, 15(5):811-816. 10.1111/j.1525-1438.2005.00141.x, 16174229.
22. Greimel E, Daghofer F, Petru E. Prospective assessment of quality of life in long-term ovarian cancer survivors. Int J Cancer 2011, 128(12):3005-3011. 10.1002/ijc.25642, 20824713.
23. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983, 67(6):361-370. 10.1111/j.1600-0447.1983.tb09716.x, 6880820.
24. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959, 32(1):50-55. 10.1111/j.2044-8341.1959.tb00467.x, 13638508.
25. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960, 23:56-62. 10.1136/jnnp.23.1.56, 495331, 14399272.
26. Smets E, Garssen B, Bonke B, De Haes C. The Multidimensional Fatigue Inventory (MFI) psychosomatic qualities of an instrument to assess fatigue. J Psychosom Res 1995, 39:315-325. 10.1016/0022-3999(94)00125-O, 7636775.
27. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85(5):365-376. 10.1093/jnci/85.5.365, 8433390.
28. Greimel ER, Bottomley A, Cull A, Waldenstrom AC, Arraras J, Chauvenet L, Holzner B, Kuljanic K, Lebrec J, D'Haese S. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-OV28) in assessing the quality of life of patients with ovarian cancer. Eur J Cancer 2003, 39(10):1402-1408. 10.1016/S0959-8049(03)00307-1, 12826043.
29. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998, 16(1):139-144.
30. Schwarz R, Krauss O, Hinz A. Fatigue in the general population. Onkologie 2003, 26(2):140-144. 10.1159/000069834, 12771522.
31. Hinz A, Schwarz R. Angst und Depression in der Allgemeinbevölkerung [Anxiety and depression in general population]. Psychothera Psychosom med Psychol 2001, 51:193-200.
32. Butler L, Bacon M, Carey M, Zee B, Tu D, Bezjak A. Determining the relationship between toxicity and quality of life in an ovarian cancer chemotherapy clinical trial. J Clin Oncol 2004, 22(12):2461-2468. 10.1200/JCO.2004.01.106, 15197209.
33. Bezjak A, Tu D, Bacon M, Osoba D, Zee B, Stuart G, Roy J-A, Piccart M, Eisenhauer E. Quality of life in ovarian cancer patients: Comparison of Paclitaxel Plus Cisplatin, With Cyclophophamide Plus Cisplatin in a randomized study. JCO 2004, 22(15):4995-4603.
34. von Gruenigen VE, Frasure HE, Jenison EL, Hopkins MP, Gil KM. Longitudinal assessment of quality of life and lifestyle in newly diagnosed ovarian cancer patients: The roles of surgery and chemotherapy. Gynecol Oncol 2006, 103:120-126. 10.1016/j.ygyno.2006.01.059, 16556458.
35. Greimel ER, Bjelic-Radisic V, Pfisterer J, Hilpert F, Daghofer F, du Bois A. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. J Clin Oncol 2006, 24(4):579-586. 10.1200/JCO.2005.02.4067, 16446330.
36. Lutgendorf SK, Anderson B, Ullrich P, Johnsen EL, Buller RE, Sood AK, Sorosky JI, Ritchie J. Quality of life and mood in women with gynecologic cancer: a one year prospective study. Cancer 2002, 94(1):131-140. 10.1002/cncr.10155, 11815969.
37. von Gruenigen VE, Huang HQ, Gil KM, Gibbons HE, Monk BJ, Rose PG, Armstrong DK, Cella D, Wenzel L. Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials. Cancer 2009, 115(20):4857-4864. 10.1002/cncr.24520, 2761522, 19691091.
38. Wan GJ, Counte MA, Cella DF. The influence of personal expectations on cancer patients' reports of health-related quality of life. Psychooncology 1997, 6(1):1-11. 10.1002/(SICI)1099-1611(199703)6:1<1::AID-PON230>3.0.CO;2-C, 9126711.
39. Doyle C, Crump M, Pintilie M, Oza AM. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer. J Clin Oncol 2001, 19(5):1266-1274.
40. Olver IN, Taylor AE, Whitford HS. Relationships between patients' pre-treatment expectations of toxicities and post chemotherapy experiences. Psychooncology 2005, 14(1):25-33. 10.1002/pon.804, 15386792.
41. Sprangers MA, Schwartz CE. The challenge of response shift for quality-of-life-based clinical oncology research. Ann Oncol 1999, 10(7):747-749. 10.1023/A:1008305523548, 10470418.
42. Rapkin B, Schwartz C. Toward a theoretical model of quality-of-life appraisal: Implications of findings from studies of response shift. Health Qual Life Outcomes 2004, 2:14. 10.1186/1477-7525-2-14, 408464, 15023229.
43. Longo DL. Interferon toxicity worse in retrospect; impact on Q-TWiST? Quality-Adjusted Time Without Symptoms or Toxicity. J Clin Oncol 1998, 16(11):3716. author reply 3718.
44. Mirabeau-Beale KL, Kornblith AB, Penson RT, Lee H, Goodman A, Campos SM, Duska L, Pereira L, Bryan J, Matulonis UA. Comparison of the quality of life of early and advanced stage ovarian cancer survivors. Gynecol Oncol 2009, 114(2):353-359. 10.1016/j.ygyno.2009.05.009, 19481244.
45. Arriba LN, Fader AN, Frasure HE, von Gruenigen VE. A review of issues surrounding quality of life among women with ovarian cancer. Gynecol Oncol 2010, 119(2):390-396. 10.1016/j.ygyno.2010.05.014, 20594586.
46. Stewart DE, Duff S, Wong F, Melancon C, Cheung AM. The views of ovarian cancer survivors on its cause, prevention, and recurrence. Medscape Womens Health 2001, 6(5):5.
47. Matulonis UA, Kornblith A, Lee H, Bryan J, Gibson C, Wells C, Lee J, Sullivan L, Penson R. Long-term adjustment of early-stage ovarian cancer survivors. Int J Gynecol Cancer 2008, 18(6):1183-1193. 10.1111/j.1525-1438.2007.01167.x, 18217977.
48. Basch E. Patient-reported outcomes in drug safety evaluation. Ann Oncol 2009, 20(12):1905-1906. 10.1093/annonc/mdp542, 19934250.
49. Holzner B, Rumpold G. Computer-based Health Evaluation System (CHES) Version 3.0 2005, Evaluation Software Development: Innsbruck.
50. Giesinger JM, Golser M, Erharter A, Kemmler G, Schauer-Maurer G, Stockhammer G, Muigg A, Hutterer M, Rumpold G, Holzner B. Do neurooncological patients and their significant others agree on quality of life ratings?. Health Qual Life Outcomes 2009, 7:87. 10.1186/1477-7525-7-87, 2770559, 19814834.
51. Meraner V, Giesinger J, Kemmler G, Taucher S, Hubalek M, Weber B, Rumpold G, Sperner-Unterweger B, Holzner B. Development of a screening tool for the identification of psychooncological treatment needs in breast cancer patients. Psychooncology 2009, 18(9):974-983. 10.1002/pon.1480, 19142844.
52. Erharter A, Giesinger J, Kemmler G, Schauer-Maurer G, Stockhammer G, Muigg A, Hutterer M, Rumpold G, Sperner-Unterweger B, Holzner B. Implementation of computer-based quality-of-life monitoring in brain tumor outpatients in routine clinical practice. J Pain Symptom Manage 2010, 39(2):219-229. 10.1016/j.jpainsymman.2009.06.015, 20152586.
53. Schwarz R, Hinz A. Reference data for the quality of life questionnaire EORTC QLQ-C30 in the general German population. Eur J Cancer 2001, 37(11):1345-1351. 10.1016/S0959-8049(00)00447-0, 11435063.
54. Scott N, Fayers P, Aaronson N, Bottomley A, De Graeff A, Groenvold M, Gundy C, Koller M, Petersen M, Sprangers M. on Behalf of the EORTC QOL Group: EORTC QLQ-C30 Reference Value 2008, Brussels: EORTC Quality of Life Group.